title: Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus.
abstract: There is a lack of surveillance data on resistance to fusidic acid (FA) in Asia, and no reviews of FA usage for the treatment of orthopaedic infections have been conducted since the year 2000. In this study, we present a systemic literature review of FA resistance in Asia and the clinical use of FA for the treatment of bone and joint infections (BJIs). The in vitro activity of FA against meticillin-resistant Staphylococcus aureus (MRSA) isolates remains good, with low (<10%) resistance rates in most Asian countries. FA in Asia appears to be a better oral anti-MRSA agent than trimethoprim/sulfamethoxazole and clindamycin. More than 80 cases of FA use for BJI have been reported since 2000 and the recurrence or failure rate is <10%. There is much evidence supporting the use of FA in combination with other antibiotics (e.g. rifampicin) as an oral treatment following intravenous glycopeptide treatment for BJIs.
authors.affiliation: Department of Internal Medicine, E-Da Hospital/I-Shou University, Kaohsiung, Taiwan.
authors.forename: Jiun-Ling
authors.initials: JL
authors.lastname: Wang
authors.forename: Hung-Jen
authors.initials: HJ
authors.lastname: Tang
authors.forename: Pang-Hsin
authors.initials: PH
authors.lastname: Hsieh
authors.forename: Fang-Yao
authors.initials: FY
authors.lastname: Chiu
authors.forename: Yen-Hsu
authors.initials: YH
authors.lastname: Chen
authors.forename: Ming-Chau
authors.initials: MC
authors.lastname: Chang
authors.forename: Ching-Tai
authors.initials: CT
authors.lastname: Huang
authors.forename: Chang-Pan
authors.initials: CP
authors.lastname: Liu
authors.forename: Yeu-Jun
authors.initials: YJ
authors.lastname: Lau
authors.forename: Kao-Pin
authors.initials: KP
authors.lastname: Hwang
authors.forename: Wen-Chien
authors.initials: WC
authors.lastname: Ko
authors.forename: Chen-Ti
authors.initials: CT
authors.lastname: Wang
authors.forename: Cheng-Yi
authors.initials: CY
authors.lastname: Liu
authors.forename: Chien-Lin
authors.initials: CL
authors.lastname: Liu
authors.forename: Po-Ren
authors.initials: PR
authors.lastname: Hsueh
mesh_terms: D000081:Acetamides / Q000008:administration & dosage / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001208:Asia; D001850:Bone Diseases, Infectious / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D004318:Doxycycline / Q000008:administration & dosage / Q000627:therapeutic use; D024881:Drug Resistance, Bacterial; D005672:Fusidic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007592:Joint Diseases / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D000069349:Linezolid; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000472:pathogenicity; D008826:Microbial Sensitivity Tests; D023303:Oxazolidinones / Q000008:administration & dosage / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology
chemical_list: D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D005672:Fusidic Acid; D000069349:Linezolid; D004318:Doxycycline